title: Potential of RAS inhibition to improve metabolic bone disorders.
abstract: Metabolic bone disorder is usually caused by abnormalities of minerals and hormones metabolism. Recently, it has been proved by several studies that the renin-angiotensin system (RAS) in local bone tissue is directly involved in bone metabolism. Activation of skeletal RAS plays an important role in bone metabolic disorders. Based on in vitro, in vivo, and clinical studies, this review explains the roles of RAS in bone metabolism and also covers the potential approaches and beneficial effects of RAS inhibition on bone health. Differential strategies for inhibiting RAS can be employed to maintain bone health, which are attributed primarily to the reduced level of angiotensin II (AngII) and suppressed stimulation of the AngII signaling pathway. The use of renin inhibitors, angiotensin-converting enzyme inhibitors, and AngII receptor blockers either individually or in combination with each other could have promising results in fighting bone metabolic disorders associated with other cardiovascular diseases as well as independent bone injuries.
authors: Center for Systems Biomedical Sciences, University of Shanghai for Science and Technology, Shanghai 200093, China.
authors: Yoseph
authors: Y
authors: Gebru
authors: Teng-Yue
authors: TY
authors: Diao
authors: Hai
authors: H
authors: Pan
authors: Emmanuel
authors: E
authors: Mukwaya
authors: Yan
authors: Y
authors: Zhang
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000378:metabolism*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008954:Models, Biological; D012084:Renin-Angiotensin System / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors
references: Osteoporos Int. 2012 Aug;23(8):2159-67
references: 22080379
references: Int Urol Nephrol. 2008;40(4):1015-25
references: 18704745
references: J Renin Angiotensin Aldosterone Syst. 2014 Sep;15(3):218-27
references: 23283823
references: Biosci Biotechnol Biochem. 2012;76(7):1367-71
references: 22785482
references: Circulation. 2008 Aug 12;118(7):773-84
references: 18695203
references: Clin Exp Pharmacol Physiol. 1993 Jan;20(1):15-20
references: 8381736
references: J Biol Chem. 2009 Feb 20;284(8):4857-64
references: 19004830
references: J Bone Miner Res. 2011 Dec;26(12):2959-66
references: 21887703
references: Biochem Biophys Res Commun. 2003 Sep 5;308(4):698-705
references: 12927775
references: Med Hypotheses. 1996 Jun;46(6):507-10
references: 8803932
references: J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):259-64
references: 22345095
references: Hypertension. 2003 Dec;42(6):1137-43
references: 14597641
references: J Natl Med Assoc. 2007 Jan;99(1):57-63
references: 17304969
references: Circulation. 2001 Feb 13;103(6):904-12
references: 11171802
references: Chem Biol. 2000 Jul;7(7):493-504
references: 10903938
references: Plast Reconstr Surg. 2008 May;121(5):1554-1566
references: 18453977
references: J Clin Hypertens (Greenwich). 2007 Sep;9(9):701-5
references: 17786071
references: J Endocrinol. 1997 Jan;152(1):5-10
references: 9014834
references: J Endocrinol. 1998 Mar;156(3):543-50
references: 9582511
references: Bone. 2006 Apr;38(4):584-8
references: 16257280
references: Clin Calcium. 2009 Jul;19(7):997-1002
references: 19567997
references: Circulation. 1998 Apr 14;97(14):1411-20
references: 9577953
references: Br J Haematol. 2004 Jul;126(1):120-6
references: 15198742
references: J Hypertens. 2006 Feb;24(2):243-56
references: 16508564
references: Int J Mol Sci. 2011;12(7):4206-13
references: 21845073
references: Nephrology (Carlton). 2012 Nov;17(8):767-73
references: 22943310
references: J Cell Physiol. 1998 Apr;175(1):89-98
references: 9491784
references: Vasc Health Risk Manag. 2009;5(1):453-63
references: 19475781
references: Cardiol Res Pract. 2010 Dec 22;2011:714515
references: 21234405
references: Crit Rev Oral Biol Med. 1999;10(1):40-57
references: 10759426
references: Proc (Bayl Univ Med Cent). 2003 Jan;16(1):123-6
references: 16278727
references: Int J Clin Pharmacol Ther. 2008 May;46(5):252-8
references: 18538111
references: Clin Sci (Lond). 2012 Aug 1;123(4):205-23
references: 22548406
references: J Bone Miner Res. 2009 Feb;24(2):241-50
references: 18847324
references: Science. 2000 Sep 1;289(5484):1504-8
references: 10968780
references: Clin Sci (Lond). 2013 May;124(9):553-66
references: 23336210
references: FASEB J. 2008 Jul;22(7):2465-75
references: 18256306
references: Genes Dev. 2006 Sep 15;20(18):2492-506
references: 16980579
references: Br J Pharmacol. 2009 Oct;158(3):771-8
references: 19694726
references: Clin Sci (Lond). 2013 Mar;124(5):307-23
references: 23157407
references: Kidney Int. 2011 Aug;80(3):245-55
references: 21633407
references: Curr Pharm Des. 2013;19(17):3049-53
references: 23176218